SCHEMBL21962811

SCHEMBL21962811

Fc1csc(CNC2CCC2)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PABPC1 P11940 1/20 0.42
HRH3 Q9Y5N1 1/20 0.36
ALDH1A1 P00352 3/20 0.36
USP2 O75604 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 2/20 0.34
POLB P06746 2/20 0.34
KDM4E B2RXH2 2/20 0.34
GLA P06280 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
KCNH2 Q12809 2/20 0.34
MAP4K4 O95819 1/20 0.33
CYP2D6 P10635 1/20 0.33
GRIN2B Q13224 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15219310 0.75 PABPC1 (0.45) PABPC1HRH3ALDH1A1USP2TSHR
SCHEMBL11919025 0.72 HRH3 (0.44) PABPC1HRH3ALDH1A1USP2TSHR
SCHEMBL11916009 0.71 CYP2D6 (0.51) PABPC1HRH3ALDH1A1USP2TSHR
SCHEMBL28469040 0.71 ALDH1A1 (0.51) PABPC1HRH3ALDH1A1TSHRHTT
SCHEMBL5460896 0.67 HRH3 (0.63) HRH3ALDH1A1POLBMEN1KMT2A
SCHEMBL26269008 0.66 HRH3 (0.56) PABPC1HRH3ALDH1A1TSHRPOLB
SCHEMBL22012906 0.65 PABPC1 (0.36) PABPC1HRH3ALDH1A1USP2TSHR
SCHEMBL13335293 0.65 OPRM1 (0.35) ALDH1A1TSHRKDM4ETDP1KCNH2
SCHEMBL28462189 0.64 KCNH2 (0.54) PABPC1HRH3ALDH1A1TSHRPOLB
SCHEMBL15587608 0.64 ALDH1A1 (0.49) PABPC1HRH3ALDH1A1TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3880659-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2024-01-03 EP disclosed
US-20230051589-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-02-16 US disclosed
US-20230051589-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-02-16 US disclosed
EP-3880659-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY Novartis AG (CH) 2021-09-22 EP disclosed
WO-2020102576-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 WO disclosed
WO-2020102576-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230051589-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP1, NLRP3, NOD1 PABPC1 595/4885HRH3 3155/4885ALDH1A1 1999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.